ACG
h.o.l.M.E.S.
Automated Clinical Guidelines
ΨΥΧΗΣ ΙΑΤΡΕΙΟΝ
SGLT-2 Inhibitors
Ertugliflozin (trade name Steglatro) is a drug for the treatment of type 2 diabetes. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin... Wikipedia
Manufacturer's Website: Steglatro Average retail cost: $425/month
Steglatro (ertugliflozin)
* Prices reflect U.S. average retail price
Dapagliflozin (INN, USAN, trade name Farxiga in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca... Wikipedia
Manufacturer's Website: Farxiga Average retail cost: $678/month
Farxiga (dapagliflozin)
Empagliflozin (trade name Jardiance) is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine... Wikipedia
Manufacturer's Website: Jardiance Average retail cost: $813/month
Jardiance (empagliflozin)
Canagliflozin (trade name Invokana or Sulisent) is a medication used for the treatment of type 2 diabetes. It is of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors class. This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to sulfonylurea derivatives and insulin. In 2017, the FDA concluded that canagliflozin causes an increased risk of leg and foot amputations. The FDA began requiring a Boxed Warning to be added to the canagliflozin drug labels to describe this risk... Wikipedia
Manufacturer's Website: Invokana Average retail cost: $736/month
Invokana (canagliflozin)
